Implant Sciences to Exhibit at Passenger Terminal Expo 2015 in Paris, France on March 10 - 12, 2015

WILMINGTON, Mass., March 10, 2015 /PRNewswire/ -- Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, announced today the Company will exhibit its QS-B220 desktop explosives trace detector at booth #3090 on March 10 – 12, 2015 at the Passenger Terminal Expo 2015 in Paris, France.

The QS-B220 was the first ETD to successfully pass the European Civil Aviation Conference's (ECAC) Common Evaluation Process of Security Equipment for airport checkpoint screening of passengers in October 2014. It is also the first and only ETD with a non-radioactive source to have received approval for air cargo screening in the 44 member nations of ECAC.

"Demand for high-performance ETDs in Europe's aviation and air cargo security sector is higher than we have seen in the recent past. This demand is driven by new regulations for security and higher standards for ETD performance. As the only ECAC-approved ETD with a non-radioactive source for cargo screening, we believe the QS-B220 is extremely well positioned to be a system of choice for European airlines and cargo facilities that prefer security equipment that does not utilize radiation," stated Dr. Darryl Jones, Implant Sciences' Vice President of  Global Sales and Marketing.

About the QS-B220 Desktop Explosives and Drugs Trace Detector

The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives as well as illicit drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.

About Implant Sciences

Implant Sciences is a leader in developing and manufacturing advanced detection capabilities to counter and eliminate the ever-evolving threats from explosives and drugs. The Company's team of dedicated trace detection experts has developed proprietary technologies used in its commercial products, thousands of which have been sold across more than 50 countries worldwide.  The Company's ETDs have received approvals and certifications from several international regulatory agencies including the TSA in the U.S., STAC in France, the German Ministry of the Interior, and the Ministry of Public Safety in China.  It also received a GSN 2013 Homeland Security Award for "Best Explosives Detection Solution".  All Implant Sciences products are recognized as Qualified Anti-Terrorism Technologies by the Department of Homeland Security. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to: the risk that there is no guaranty that U.S. or foreign government and law enforcement agencies or commercial consumers will purchase any of our products or that any new products we may develop will be accepted by the TSA or by such other governments, agencies or consumers; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:

Implant Sciences Corporation

Company Contact:
Mike Turmelle, Director
978-752-1700 x 116    

or

Investor Contact:
Laurel Moody
646-810-0608

SOURCE Implant Sciences Corporation

Related Links

http://www.implantsciences.com